EUVIMEDEUVIMED entdecken
QuerschnittstudieOpen Access · CC BY 4.0

Gustatory dysfunction under talquetamab therapy in multiple myeloma: a cross-sectional study of patient-reported course, nutritional changes, and quality of life

Anna Fleischer iD, Carolin Burger, Magdalena Roll, Franziska Panther, Patrick-Pascal Strunz, Jessica Peter, Sofie-Katrin Kadel, Anja Gesierich, Julia Mersi, Johannes Waldschmidt, Martin Kortüm, Hermann Einsele und 2 weitere

Supportive Care in Cancer · 2026-10 · 34 (10)

DOI: 10.1007/s00520-026-11288-4 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift Supportive Care in Cancer, online erschienen am 05.10.2026. Verfasst von Anna Fleischer und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacherstr. 6, 97080, Würzburg, Germany. Fleischer_A@ukw.de. Hauptthemen laut MEDLINE: Multiple Myeloma, Quality of Life, Taste Disorders, Antineoplastic Agents. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The purpose of this study is to characterize patient-reported taste disturbances, recalled symptom course, nutritional changes, and quality of life in patients with relapsed/refractory multiple myeloma treated with talquetamab. This single-center cross-sectional study combined taste-strip testing with a study-specific questionnaire, EORTC QLQ-C30, and PHQ-4 in 32 patients. Analyses used recorded aggregate correct-identification counts without a normative hypogeusia classification. Symptom timing and changes since treatment initiation were recalled at one assessment. All patients reported taste disturbances during therapy. The median identification count was 2.5 (interquartile range 0.75–7.25); eight patients had no correct identifications. Twenty-three (71.9%) described onset within 14 days. Current appetite reduction was reported by 20 patients (62.5%), whose mean identification count was lower than that of the other 12 patients (2.45 versus 7.83; mean difference − 5.38, 95% confidence interval − 8.20 to − 2.57; p = 0.0006). Sixteen patients (50.0%) reported directional weight loss, with a median loss of 4.5 kg. Ten (31.3%) had considered stopping talquetamab; seven explicitly cited taste disturbance. Mean global health status was 50.5/100 and correlated with identification count ( r = 0.406; p = 0.021). Taste disturbances co-occurred with substantial nutritional concerns. Lower taste-identification counts were associated with current appetite reduction and lower global health status. The findings support attention to taste-related burden but do not establish causality, sustained recovery, or effects on adherence. Prospective evaluations of supportive care are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaQuality of LifeTaste DisordersAntineoplastic AgentsHumansCross-Sectional StudiesFemaleMaleMiddle AgedAgedSurveys and QuestionnairesNutritional StatusAged, 80 and overAppetiteAntibodies, Bispecific

Stichwörter der Autor:innen

AppetiteDysgeusiaMultiple myelomaQuality of lifeSupportive careTalquetamab

Substanzen

Antineoplastic AgentstalquetamabAntibodies, Bispecific

Autor:innen und Institutionen

  • Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacherstr. 6, 97080, Würzburg, Germany. Fleischer_A@ukw.de.
  • Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacherstr. 6, 97080, Würzburg, Germany.

ORCID-Profile: Anna Fleischer

Zitieren

APA

Fleischer, A., Burger, C., Roll, M., Panther, F., Strunz, P. P., Peter, J., Kadel, S. K., Gesierich, A., Mersi, J., Waldschmidt, J., Kortüm, M., Einsele, H., Maatouk, I., & Rasche, L. (2026). Gustatory dysfunction under talquetamab therapy in multiple myeloma: a cross-sectional study of patient-reported course, nutritional changes, and quality of life. Supportive Care in Cancer, 34(10). https://doi.org/10.1007/s00520-026-11288-4

Vancouver

Fleischer A, Burger C, Roll M, Panther F, Strunz PP, Peter J, et al. Gustatory dysfunction under talquetamab therapy in multiple myeloma: a cross-sectional study of patient-reported course, nutritional changes, and quality of life. Supportive Care in Cancer. 2026;34(10). doi:10.1007/s00520-026-11288-4

BibTeX
@article{Fleischer2026,
  author = {Fleischer, Anna and Burger, Carolin and Roll, Magdalena and Panther, Franziska and Strunz, Patrick-Pascal and Peter, Jessica and Kadel, Sofie-Katrin and Gesierich, Anja and Mersi, Julia and Waldschmidt, Johannes and Kortüm, Martin and Einsele, Hermann and Maatouk, Imad and Rasche, Leo},
  title = {Gustatory dysfunction under talquetamab therapy in multiple myeloma: a cross-sectional study of patient-reported course, nutritional changes, and quality of life},
  journal = {Supportive Care in Cancer},
  year = {2026},
  volume = {34},
  number = {10},
  doi = {10.1007/s00520-026-11288-4}
}
Kostenlos starten →